CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 5, 2011, Pages 393-400

  Franco, David ^a   Liu, Weimin ^b   Gardiner, David F ^a   Hahn, Beatrice H ^b,c   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

baculovirus gp64; CD40; CD40L; Gag p24; HIV 1; immune response; vaccine; virus like particle

Indexed keywords

CD40 LIGAND; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VACCINATION; VIRUS LIKE AGENT;

AIDS VACCINES; ANIMALS; ANTIGENS, CD40; CD40 LIGAND; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; SPODOPTERA; T-LYMPHOCYTES; VIRION;

EID: 79953056393     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820b844e     Document Type: Article

References (44)

1. Cohen MS, Hellmann N, Levy JA, et al. The spread, treatment, and prevention of HIV-1: evolution of a global epidemic. J Clin Invest. 2008; 118:1244-1254. (Pubitemid 351500417)
2. Karlsson GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol. 2008;2:143-155.
3. Johnson RP, Desrosiers RC. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol. 1998; 10:436-443. (Pubitemid 28393827)
4. Johnson RP, Lifson JD, Czajak SC, et al. Highly attenuated vaccine strains of Simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol. 1999;73:4952-4961. (Pubitemid 29246756)
5. Sawai ET, Hamza MS, Ye M, et al. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J Virol. 2000;4:2038-2045. (Pubitemid 30434064)
6. Gay B, Tournier J, Chazal N, et al. Morphopoietic determinants of HIV-1 gag particles assembled in baculovirus-infected cells. Virology. 1998;247: 160-169. (Pubitemid 28384007)
7. Young KR, McBurney SP, Karkhanis LU, et al. Virus-like particles: designing an effective AIDS vaccine. Methods. 2006;40:98-117. (Pubitemid 44415502)
8. gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 2001;49:35-47. (Pubitemid 32146577)
9. Haffar O, Garrigues J, Travis B, et al. Human immunodeficiency viruslike, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol. 1990;46:2653-2659. (Pubitemid 20171251)
10. Wagner R, Fliessbach H, Wanner G, et al. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch Virol. 1992;127:117-137.
11. Yao Q, Kuhlmann FM, Eller R, et al. Production and characterization of simian-human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses. 2000;16:227-236. (Pubitemid 30111959)
12. Garnier L, Ratner L, Rovinski B, et al. Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol. 1998;72: 4667-4677. (Pubitemid 28215641)
13. Notka F, Stahl-Hennig C, Dittmer U, et al. Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine. 1999;18:291-301. (Pubitemid 29444003)
14. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008; 26:686-696.
15. Vietheer PT, Boo I, Drummer HE, et al. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther. 2007;12:477-487. (Pubitemid 47041146)
16. Ramqvist T, Andreasson K, Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther. 2007;7:997-1007. (Pubitemid 47204356)
17. Schirmbeck R, Böhm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology. 1996;39:111-119.
18. Zhang T, Xu Y, Qiao L, et al. Trivalent human papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine. 2010;28:3479-3487.
19. Palmer KE, Jenson AB, Kouokam JC, et al. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer. Exp Mol Pathol. 2009;86:224-233.
20. Schiller JT, Castellsagué X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26:53-61.
21. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779. (Pubitemid 32983013)
22. Bonifaz L, Bonnyay D, Mahnke K, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196:1627-1638. (Pubitemid 36026474)
23. Kelleher M, Beverley PC. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential. J Immunol. 2001;167:6247-6255. (Pubitemid 33081554)
24. Mackay MF, Barth RJ, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukocyte Biol. 1998;63:418-428. (Pubitemid 28163181)
25. Ehrhardt RO, Harriman GR, Inman JK, et al. Differential activation requirements of isotype-switched B cells. Eur J Immunol. 1996;26:1926-1934. (Pubitemid 26283171)
26. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922. (Pubitemid 24140434)
27. Seo SH, Jin HT, Park SH, et al. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine. 2009;27:5906-5912.
28. Xu H, Zhao G, Huang X, et al. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. J Gene Med. 2010;12:97-106.
29. Buonaguro L, Buonaguro FM, Tornesello ML, et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 2001;49:35-47. (Pubitemid 32146577)
30. Rovinski B, Haynes JR, Cao SX, et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J Virol. 1992;66:4003-4012.
31. Mittler E, Kolesnikova L, Strecker T, et al. Role of the transmembrane domain of Marburg virus surface protein GP in assembly of the viral envelope. J Virol. 2007;8:3942-3948. (Pubitemid 46586890)
32. Boscardin SB, Hafalla JC, Masilamani RF, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med. 2006;203:599-606.
33. Franco D, Li W, Qing F, et al. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine. 2010;28: 5676-5685.
34. Skountzou I, Quan FS, Gangadhara S, et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol. 2007;81: 1083-1094. (Pubitemid 46167831)
35. Zhang R, Zhang S, Li M, et al. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine. 2010;28: 5114-27.
36. Lin FC, Peng Y, Jones LA, et al. Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle simian immunodeficiency viruses enhances immunogenicity. J Virol. 2009;83:1216-1227.
37. Fanslow WC, Srinivasan S, Paxton R, et al. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol. 1994;5: 267-278. (Pubitemid 124001524)
38. Graf D, Muller S, Korthauer U, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25: 1749-1754.
39. Pullen SS, Labadia ME, Ingraham RH, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry. 1999;38:10168-10177.
40. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol. 1995;2:1075-1082.
41. Wyzgol A, Müller N, Fick A, et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183:1851-1861.
42. Wang BZ, Liu W, Kang SM, et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol. 2007;81:10869-10878. (Pubitemid 47536061)
43. Yang DG, Chung YC, Lai YK, et al. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol Ther. 2007;15:989-996.
44. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via antigen-presenting cell activation. J Exp Med. 1996;184:747-752. (Pubitemid 26324129)